(:QTNT)

Dec 29, 2022 09:58 am ET
Thinking about buying stock in Quotient, TAL Education, Core Scientific, TG Therapeutics, or Rivian Automotive?
NEW YORK, Dec. 29, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, TAL, CORZ, TGTX, and RIVN.
Dec 12, 2022 04:05 pm ET
Quotient Limited Announces Intent to Voluntary Delist from the Nasdaq Global Market
Quotient Limited (Nasdaq: QTNT) (the "Company") today announced that it has given formal notice to the Nasdaq Stock Market LLC ("Nasdaq") of its intention to voluntarily delist its ordinary shares from the Nasdaq Global Market. In order to...
Nov 02, 2022 05:01 pm ET
Quotient Limited Announces Reverse Stock Split Effective Today
Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that a reverse split of its ordinary shares, nil par value ("Ordinary Shares"), at a ratio of 1-for-40 became effective following close of...
Nov 01, 2022 10:45 am ET
Thinking about buying stock in Quotient, Meta Platforms, Mullen Automotive, Akerna, or Li Auto?
NEW YORK, Nov. 1, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, META, MULN, KERN, and LI.
Oct 31, 2022 06:30 am ET
Quotient Limited Announces Intent to Effect Reverse Stock Split
Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced that it will effect a one-for-40 reverse stock split ("Reverse Stock Split") of its ordinary shares, nil par value ("Ordinary Shares") that...
Sep 09, 2022 11:29 am ET
Thinking about buying stock in Nio, Quotient, Mogu, Rivian Automotive, or LYFT?
NEW YORK, Sept. 9, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NIO, QTNT, MOGU, RIVN, and LYFT.
Sep 08, 2022 08:30 am ET
Quotient Limited Selected to Join the World Economic Forum New Champions Community
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced it was selected by the World Economic Forum to join their New Champions Community. "We are delighted to...
Aug 24, 2022 08:00 am ET
Quotient Limited Expands MosaiQ Innovator’s Circle to Empower Patient Care and Laboratory Efficiencies
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient), headquartered in Eysins, Switzerland, today announced the National Screening Laboratory of Sanquin Blood Supply Foundation, Department Research & Labservices...
Aug 23, 2022 10:59 am ET
Thinking about buying stock in Avaya Holdings, Quotient, Aurora Cannabis, Marin Software, or Macy's?
NEW YORK, Aug. 23, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVYA, QTNT, ACB, MRIN, and M.
Aug 09, 2022 07:00 am ET
Quotient Limited Provides First Quarter Fiscal 2023 Results and Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its first quarter fiscal 2023 key financial results and provided an update on recent business...
Aug 02, 2022 04:05 pm ET
Quotient Limited to Report First Quarter Fiscal 2023 Financial Results and Host Conference Call on August 9th
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2022 will be released before market open on Tuesday, August 9, 2022. Title:Quotient...
Jul 12, 2022 07:30 am ET
Quotient Limited and InfYnity Biomarkers Announce Partnership to Expand MosaiQ Infectious Disease Menu
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with InfYnity Biomarkers, an R&D firm dedicated to utilizing biomarkers for the management of infectious and immunology diseases, under which the...
Jul 01, 2022 04:15 pm ET
Quotient Limited Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Steven Zuiderwijk, who has been appointed as the Chief Strategy & Business Development Officer of the...
Jun 29, 2022 08:47 am ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares and Pre-Funded Warrants
Quotient Limited (Nasdaq: QTNT) (the "Company"), a commercial-stage diagnostics company, announced the closing of its previously announced underwritten public offering of 32,458,336 ordinary shares and pre-funded warrants to purchase 34,208,331...
Jun 24, 2022 08:28 am ET
Quotient Limited Announces Pricing of Underwritten Offering
Quotient Limited (Nasdaq: QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 66,666,667 ordinary shares and ordinary share equivalents for aggregate gross proceeds of $20.0...
Jun 24, 2022 07:00 am ET
Quotient Limited Provides Fourth Quarter Fiscal 2022 Results and Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2022 key financial results and provided an update on recent business...
Jun 23, 2022 06:08 pm ET
Quotient Limited Announces Proposed Amendments to Senior Secured Notes
Quotient Limited (Nasdaq: QTNT) (the Company), a commercial-stage diagnostics company, today announced that in connection with the public offering announced today, the Company has agreed with the beneficial owners of all $132.9 aggregate principal...
Jun 23, 2022 05:55 pm ET
Quotient Limited Announces Proposed Underwritten Offering
Quotient Limited (Nasdaq: QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of $20 million of its ordinary shares and, to certain investors in lieu of...
Jun 21, 2022 04:56 pm ET
Quotient Limited Reschedules Fourth Quarter and Full Year 2022 Financial Results Announcement to Friday, June 24th and Provides a Preview of Financials
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it is rescheduling the release of its financial results for the fourth quarter and full year 2022 ended March 31, 2022. The Company will release these...
Jun 17, 2022 07:02 am ET
Quotient Limited to Report Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on June 22nd
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2022 will be released before market open on Wednesday, June 22, 2022....
Jun 08, 2022 06:44 am ET
Quotient Limited and Theradiag Announce Partnership to Advance Autoimmune Disease Diagnostics
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced an agreement with Theradiag, a market leader in autoimmune disease testing and pioneer in theranostics, under which the two companies will partner to advance...
May 17, 2022 09:17 am ET
Quotient Limited Announces Opening of Office in Dubai, United Arab Emirates
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the opening of its new office in Dubai, UAE, and the incorporation of its subsidiary Quotient Middle-East and Africa FZ LLC, as part of its ongoing expansion...
May 12, 2022 08:30 am ET
Quotient Limited to Host Key Opinion Leader Webinar on its MosaiQ™ Solution
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it will host a key opinion leader (KOL) webinar on the current landscape and unmet needs within blood grouping and donor disease screening on Monday, May...
Apr 26, 2022 08:30 am ET
Quotient Limited Announces Appointment of New Board Member
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the appointment of Thomas Aebischer to Quotient Board of Directors effective as of May 1, 2022. Mr. Aebischer will also serve on the Board's Audit Committee....
Mar 21, 2022 07:00 am ET
Quotient Limited Further Strengthens Scientific and Medical Synergies with the Expansion of the MosaiQ Innovator’s Circle
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced New York Blood Center, Inc., USA, and Centro de Transfusiones de la Comunidad de Madrid, Spain have joined...
Mar 08, 2022 06:45 am ET
Quotient Limited Announces Receipt of CE Mark for the Extended Immunohematology Microarray
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced it has received Conformité Européenne (CE) Mark for its MosaiQ Extended Immunohematology (IH) Microarray....
Feb 22, 2022 09:00 am ET
Quotient Limited to Participate in the Cowen 42nd Annual Health Care Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the Cowen 42nd Annual Health Care Conference. As part of the conference, the Company will be...
Feb 08, 2022 07:00 am ET
Quotient Limited Reports Third Quarter Fiscal 2022 Results and Provides Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2022 key financial results and furnished an update on recent business...
Feb 03, 2022 08:30 am ET
Quotient Limited to Participate in the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the management team will participate in the virtual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference. As part of the...
Feb 02, 2022 08:30 am ET
Quotient Limited Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Esteban Uriarte, who has been appointed as the Chief Manufacturing Operations Officer of the Company...
Feb 01, 2022 08:40 am ET
Quotient Limited Provides MosaiQ Regulatory & Commercial Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today announced its attendance for the first time to the Arab Health and Medlab Middle East Conference in Dubai, United Arab Emirates....
Jan 31, 2022 04:30 pm ET
Quotient Limited to Report Third Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2021 will be released before market open on Tuesday, February 8, 2022. Quotient will...
Jan 26, 2022 08:30 am ET
Quotient Limited Launches Scientific Advisory Board and Research Programs
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company headquartered in Eysins, Switzerland, today provided a Scientific Advisory Board and Research Program update. Quotient’s Senior Management and Research and Development teams...
Dec 15, 2021 08:30 am ET
Quotient Limited Provides Update on MosaiQ Expanded Immunohematology Microarray CE Marking Progress
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced the company received feedback from the European notified body on the Expanded Immunohematology (IH) submission. The Company is pleased with the feedback and...
Nov 30, 2021 08:30 am ET
Quotient Limited Announces Appointment of Chief Manufacturing Operations Officer
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced Mr. Esteban Uriarte as the Company’s Chief Manufacturing Operations Officer (CMOO). Mr. Uriarte will assume the responsibilities of CMOO on February 1st, 2022....
Nov 19, 2021 08:20 am ET
Quotient Limited Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Ali Kiboro, who has been appointed as the Chief Financial Officer of the Company effective November 1,...
Nov 15, 2021 06:56 pm ET
Quotient Limited Provides Second Quarter Fiscal 2022 Results
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its financial results for the second quarter of fiscal year 2022 and filed the quarterly report...
Nov 12, 2021 04:15 pm ET
Quotient Limited to Participate in the Jefferies London Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the management team will present at the Jefferies London Healthcare Conference on Tuesday, November 16, 2021 at 8:40am GMT (3:40am ET). A webcast...
Nov 08, 2021 04:05 pm ET
Quotient Limited Provides Business Update and Delays Releasing Second Quarter Fiscal 2022 Results
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that it will provide a business update as scheduled tomorrow, November 9th 2021 but the release...
Oct 26, 2021 08:00 am ET
Quotient Limited to Report Second Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that financial results for its fiscal second quarter ended September 30, 2021 will be released before market open on Tuesday, November 9, 2021....
Oct 14, 2021 08:45 am ET
Quotient Limited Announces receipt of Note Holders Consents to Indenture Amendments That Extend Maturity, Defer Principal Payments on 12% Senior Secured Notes
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has received unanimous consents from the holders of its 12% Senior Secured Notes (the Notes) to certain amendments to the Indenture governing...
Oct 12, 2021 08:45 am ET
Quotient Limited Announces Appointment of Chief Financial Officer
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced Ali Kiboro as the Company’s Chief Financial Officer (CFO). Mr. Kiboro will assume the responsibilities of CFO on November 1st, 2021, replacing Mr. Peter Buhler...
Oct 05, 2021 07:45 am ET
Quotient Limited Announces Appointment of Chief Commercial Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced Mohammad El Khoury as the Company’s Chief Commercial Officer. In this role, Mr. El Khoury will oversee all commercial activities for the company as it...
Oct 04, 2021 08:30 am ET
Quotient Limited Announces Appointment of New Chief Scientific & Medical Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Dr. Christine Ginocchio as Chief Scientific & Medical Officer (CSMO). “We are delighted to welcome Dr. Ginocchio in this important new role...
Oct 01, 2021 06:00 am ET
Quotient Limited Provides Update on CE Marking Progress of the MosaiQ™ Expanded Immunohematology Microarray
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the launch of the review process of the Expanded Immunohematology (IH) technical file dossier for review by the European notified body. The...
Sep 01, 2021 08:21 am ET
Quotient Limited Announces Christian Albrich as Chief People Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that Christian Albrich has been appointed as Chief People Officer of the Company and will begin...
Aug 11, 2021 07:45 am ET
Quotient Limited Announces Departure of Chief Commercial Officer, Jeremy Stackawitz
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), announced that Jeremy Stackawitz has notified the Company that he is resigning from his position as Chief Commercial Officer. "I would like to thank Jeremy for...
Aug 05, 2021 06:30 am ET
Quotient Limited Provides First Quarter Fiscal 2022 Results and Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its first quarter fiscal 2022 key achievements and summarized recent business developments....
Aug 02, 2021 04:30 pm ET
Quotient Limited Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the grant of equity awards to Dr. Michael Hausmann, who has been appointed as the Chief Technology Officer of the Company effective August 1,...
Jul 29, 2021 08:30 am ET
Quotient Limited to Report First Quarter Fiscal Year 2022 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2021 will be released before market open on Thursday, August 5, 2021. Quotient will host a...
Jul 02, 2021 04:30 pm ET
Quotient Limited Announces Departure of Chief Financial Officer, Peter Buhler
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), announced that Peter Buhler has notified the Company that he is resigning from his position as Chief Financial Officer to take a position with another company....
Jun 01, 2021 06:30 am ET
Quotient Limited Provides Fourth Quarter and Full Year Fiscal 2021 Results and provides Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its fourth quarter fiscal 2021 key achievements and summarized recent business developments....
May 31, 2021 08:00 am ET
Quotient Limited to Participate in Upcoming Investor Conferences
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the management team will participate in two upcoming investor conferences. Jefferies Virtual Healthcare ConferenceDate: Wednesday, June 2, 2021Presentation...
May 25, 2021 08:30 am ET
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2021 will be released before market open on Tuesday, June 1, 2021. Quotient...
May 24, 2021 08:00 am ET
Quotient Limited Announces New $95 Million Financing Led by Highbridge
Quotient Limited ("Quotient") (NASDAQ: QTNT), a commercial-stage diagnostics company, today announced that it has agreed to sell $95.0 million aggregate principal amount of its new 4.75% Convertible Senior Notes due 2026 (the "Notes") in a private...
Apr 12, 2021 09:00 am ET
MosaiQ by Quotient Wins Prestigious Red Dot Design Award
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the company has been recognized with a 2021 Red Dot Product Design Award for the full MosaiQ™ by Quotient system. MosaiQ is designed to...
Apr 05, 2021 04:05 pm ET
Quotient Limited Reports Further Enhanced Multimodal Capabilities of the MosaiQ Technology
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported encouraging result from a study of its MosaiQ Multiplex Molecular Disease Screening (MDS) Microarray, and provided an update regarding progress on...
Mar 01, 2021 08:00 am ET
Quotient Limited Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the scheduled grant of equity awards to Mr. Manuel Mendez, who has been appointed as the Chief Executive Officer of the Company effective April 1,...
Feb 24, 2021 04:05 pm ET
Quotient Limited to Participate in the Cowen 41st Annual Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that the Company will present at the Cowen 41st Annual Healthcare Conference on Monday, March 1, 2021 at 1:20pm ET. A webcast of the presentation...
Feb 23, 2021 06:20 am ET
Quotient Limited Announces Manuel Mendez as Chief Executive Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that Manuel Mendez has been appointed as Chief Executive Officer of the Company and will begin serving in that role on April 1st, 2021. Franz...
Feb 12, 2021 09:00 am ET
Quotient Limited Participate in the BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced the Company will participate in the BTIG Virtual MedTech, Digital Health, Life Science &...
Feb 01, 2021 06:00 am ET
Quotient Limited Reports Third Quarter Fiscal 2021 Results and Business Update
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its third quarter fiscal 2021 results and other notable developments. Notable developments...
Jan 19, 2021 08:00 am ET
Quotient Limited to Report Third Quarter 2021 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021. Quotient will host...
Jan 12, 2021 09:10 am ET
Quotient Limited Wins 2021 BIG Innovation Award
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced it has been named a winner in the prestigious 2021 BIG Innovation Awards presented by the Business Intelligence Group. The annual awards program...
Dec 22, 2020 04:05 pm ET
Quotient Limited Announces Departure of Chief Operating Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that on December 21, 2020, Ed Farrell delivered a notice of resignation from his position as the Company's Chief Operating Officer. Under Mr....
Dec 10, 2020 08:30 am ET
Quotient Limited Provides Status Update on the Initial SDS Microarray and MosaiQ Instrument for the US Market
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced that it received a request from the U.S. Food and Drug Administration (FDA) for additional testing data regarding the 510(k) application for the...
Nov 30, 2020 04:05 pm ET
Quotient Limited Announces MosaiQ™ Expanded IH EU Field Trial Performance Data
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported preliminary EU field trial performance data for its MosaiQ Expanded Immunohematology (IH) Microarray. The data suggest that tests performed with...
Nov 09, 2020 04:05 pm ET
Quotient Limited to Participate in Two Upcoming Conferences
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company will participate in two upcoming virtual investor conferences. Stifel Virtual...
Nov 02, 2020 06:00 am ET
Quotient Limited Reports Second Quarter Fiscal 2021 Results and Business Update
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its second quarter fiscal 2021 results and summarized recent key developments. Quotient...
Oct 19, 2020 08:48 am ET
Quotient Limited to Report Second Quarter 2021 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2020 will be released before market open on Monday, Nov 2, 2020. Quotient will host a...
Sep 28, 2020 07:00 am ET
Quotient Limited Announces Receipt of U.S. FDA Emergency Use Authorization (EUA) for MosaiQ COVID-19 Antibody test
Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that on September 25, 2020, the U.S. Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for Quotient's COVID-19 antibody test. The...
Sep 15, 2020 04:05 pm ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ: QTNT) (the "Company"), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 20,294,117 ordinary shares at a price to the public of $4.25 per share,...
Sep 10, 2020 08:42 pm ET
Quotient Limited Announces Upsize and Pricing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the upsize and pricing of a $75 million underwritten public offering.  The Company is offering 17,647,059 ordinary shares at a price to the...
Sep 09, 2020 04:05 pm ET
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ: QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of $60 million of its ordinary shares. All of the ordinary shares to be sold in...
Sep 08, 2020 06:15 am ET
Quotient Limited and Ortho Clinical Diagnostics Settle Arbitration and Sign Binding Letter of Intent Covering Patient Transfusion Diagnostics
Quotient Limited (NASDAQ:QTNT), headquartered in Eysins, Switzerland, today announced that the Company and Ortho Clinical Diagnostics (Ortho) have signed a binding letter of intent that confirms the termination of their former distribution...
Aug 27, 2020 08:30 am ET
Bloodworks Northwest Now Tests All Donors for COVID-19 Antibodies Looking for More Qualified Convalescent Plasma Donors
Bloodworks Northwest is now offering all blood donors across the Pacific Northwest free COVID-19 antibody testing with the possibility of discovering more qualified COVID-19 Convalescent Plasma (CCP) Donors. The testing is done with Quotient’s...
Aug 04, 2020 09:15 am ET
Quotient Limited to Publish Quarterly Investor Presentation
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today published the latest investor presentation associated with the earnings call for fiscal quarter ended June 30, 2020. A copy of the Company’s investor presentation will...
Aug 03, 2020 06:00 am ET
Quotient Limited Reports First Quarter Fiscal 2021 Results and Business Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today reported its first quarter fiscal 2021 results and summarized recent key developments. Quotient...
Jul 23, 2020 08:30 am ET
Quotient Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland today announced that Dr. Isabelle Buckle, Ph.D. and Dr. Catherine Larue, Ph.D. will join the Company’s Board of Directors,...
Jul 23, 2020 08:15 am ET
Quotient Announces Appointment of Two New Board Members
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced changes in the composition of its board of directors that will take effect later this year.  Two of the...
Jul 20, 2020 06:00 am ET
Quotient Limited Reports Impressive Results from an Independent SARS-CoV-2 Antibody Detection Study Conducted in Spain
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported that an independent study conducted in Madrid, Spain has confirmed the high performance characteristics of...
Jul 17, 2020 08:00 am ET
Quotient Limited to Report First Quarter 2021 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2020 will be released before market open on Monday, August 3, 2020. Quotient will host a...
Jul 01, 2020 08:00 am ET
Quotient Limited Added to the Russell 2000 and Russell 3000 Indexes
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today announced that the Company has been added to the Russell 2000® and 3000® Indexes, effective June 29, 2020...
Jun 09, 2020 06:00 am ET
Quotient Limited Provides Update on COVID-19 Antibody Test Progress, Other Key Developments and Fourth Quarter and Full Year Fiscal 2020 Results
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today summarized recent key achievements. These included Quotient's rapid development of a high performance...
May 26, 2020 04:30 pm ET
Quotient Limited to Participate in the Jefferies Virtual Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the Company will present at the Jefferies Virtual Healthcare Conference on Tuesday, June 2, 2020 at 9:00 a.m. ET. A webcast of the presentation will be...
May 26, 2020 08:00 am ET
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2020 will be released before market open on Tuesday, June 9, 2020. Quotient...
May 11, 2020 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Cytokinetics, Quotient, Myriad Genetics, or Avaya Holdings?
NEW YORK, May 11, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, CYTK, QTNT, MYGN, and AVYA.
May 11, 2020 02:00 am ET
Quotient Limited and hVIVO Announce Partnership to Support Wide-Spread COVID-19 Antibody Testing in the UK
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, and hVIVO, part of Open Orphan plc (LONDON:ORPH), today announced that the MosaiQ™ by Quotient system and MosaiQ COVID-19 Antibody...
May 01, 2020 09:00 am ET
Quotient Limited Announces CE Mark for its SARS-CoV-2 (COVID-19) Antibody Microarray
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has completed the process for declaring conformity to the essential requirements of the In Vitro...
Apr 28, 2020 09:31 am ET
Thinking about buying stock in Quotient, Eldorado Resorts, Carnival Corp, Inovio Pharmaceuticals, or American Eagle Outfitters?
NEW YORK, April 28, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for QTNT, ERI, CCL, INO, and AEO.
Apr 27, 2020 04:05 pm ET
Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Final Performance Data
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported very strong final study performance data for its SARS-CoV-2 antibody test. The Company expects to complete...
Apr 21, 2020 04:05 pm ET
Quotient Limited Announces SARS-CoV-2 (COVID-19) Antibody Test Performance Update
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive performance data for its SARS-CoV-2 antibody test. Based on these results, under applicable...
Apr 06, 2020 08:00 am ET
Quotient Limited Announces the Completion of the SARS-CoV-2 Antibody Test Development
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the completion of the development phase of a microarray based SARS-CoV-2 (COVID-19) antibody test for the...
Mar 13, 2020 04:30 pm ET
Quotient Limited to Host Investor Information Conference Call and Live Webcast
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Company will host an investor information conference call and live webcast on March 25, 2020 at 8:00 am...
Feb 24, 2020 04:05 pm ET
Quotient Limited Reports Concordance Data from Extended Serological Disease Screening Benchmark Study
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ multimodality multiplex Extended Serological Disease Screening...
Feb 14, 2020 08:04 am ET
Quotient Limited Announces CE Mark Approval for Initial Serological Disease Screening Microarray
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced that it has received the Conformité Européene (CE) Mark approval for the Initial Serological Disease...
Jan 30, 2020 06:00 am ET
Quotient Limited Provides an Update on Recent MosaiQ Milestone Achievements together with Third Quarter Fiscal 2020 Results
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (Quotient or the Company), headquartered in Eysins, Switzerland, today re-capped recently disclosed milestone achievements which included the completion of a third party...
Jan 21, 2020 08:00 am ET
Quotient Limited to Report Third Quarter 2020 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2019, will be released before market open on Thursday, January 30, 2020. Quotient will...
Jan 10, 2020 04:05 pm ET
Quotient Limited Provides an Update on Recent Milestone Achievements for its MosaiQ Multimodality Multiplexing Diagnostic Platform
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the commencement of the EU field trial activities for the extended Immunohematology (IH) microarray. In...
Jan 08, 2020 08:00 am ET
Quotient Announces Equity Awards
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial Officer (CFO), effective as of February 5, 2020. In connection with the planned appointment, on...
Jan 07, 2020 04:05 pm ET
Quotient Announces Appointment of New Chief Financial Officer Peter Buhler and Chief Operating Officer Ed Farrell
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the planned appointment of Peter Buhler as Chief Financial Officer (CFO) replacing Chris Lindop, the current CFO who plans to retire in May 2020. Mr. Buhler...
Dec 05, 2019 04:05 pm ET
Quotient Limited Reports Concordance Data from MDS Concept Study
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today reported positive concordance data for its MosaiQ™ Multiplex Molecular Disease Screening (MDS) Microarray confirming...
Nov 18, 2019 09:00 am ET
Quotient Limited to Participate in the Jefferies 2019 London Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Executive Officer, Franz Walt, the Company’s President of R&D and Manufacturing, Ed Farrell, and the Company’s Chief Financial...
Nov 12, 2019 04:05 pm ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 13,800,000 ordinary shares at a price to the public of $7.00 per share,...
Nov 06, 2019 10:00 pm ET
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 12,000,000 ordinary shares at a price to the public of $7.00 per share....
Nov 06, 2019 04:20 pm ET
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will...
Nov 04, 2019 06:00 am ET
Quotient Limited Provides Positive Updates on MosaiQ’s Initial Serological Disease Screening and Expanded Immunohematology Microarrays, on Hypercare Launch and on a Successful Facility Audit and Repor
Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, provided updates on several important developments in connection with the transformational MosaiQ multiplexing platform. These included successful...
Oct 31, 2019 08:00 am ET
Quotient Announces Positive Preliminary Results from the Initial Serological Disease Screening US Field Trial
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced positive preliminary US field trial data on the Initial Serological Disease Screening (SDS) Microarray. “We are very encouraged by these results. The Initial...
Oct 21, 2019 06:00 am ET
Quotient Limited to Report Second Quarter 2020 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2019, will be released before market open on Monday, November 4, 2019. Quotient will...
Oct 17, 2019 04:51 pm ET
Quotient Announces Positive Verification and Validation Results for Extended Immunohematology Microarray and Updates on Hypercare Sites and Revenue Performance in the Quarter
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the positive Verification & Validation (V&V) data for the Extended Immunohematology (IH) Microarray. “We received encouraging feedback from the ongoing...
Aug 05, 2019 06:15 am ET
Quotient Limited Provides Updates on European Hypercare Launch, the CE Mark Submission and U.S. Field Trial for the Initial Serological Disease Screening Microarray, and Reports First Quarter Fiscal 2
Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today provided an update on the commencement of its EU hypercare launch during July 2019; on the completion of its initial Serological Disease...
Jul 22, 2019 08:00 am ET
Quotient Limited to Report First Quarter 2020 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2019, will be released before market open on Monday, August 5, 2019. Quotient will host a...
Jul 02, 2019 08:00 am ET
Quotient Board Announces Contract Extension of CEO Franz Walt
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the Board of Directors’ decision to amend Chief Executive Officer (CEO) Franz Walt’s employment agreement to...
Jul 01, 2019 07:00 am ET
Quotient Limited Announces the Submission of the Initial SDS Microarray CE mark Filing for MosaiQ™
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced the submission of its completed dossier for the CE Mark (Conformité Européenne) of its initial Serological...
Jun 05, 2019 08:00 am ET
Quotient Limited to Participate in the Raymond James Life Sciences and MedTech Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop, will present at the inaugural Raymond James Life Sciences and MedTech Conference on Wednesday, June...
May 28, 2019 06:00 am ET
Quotient Limited Recaps Recent Milestone Achievement and Updates on the Initial Serological Disease Screening CE Mark Submission, planned 2019 US Field Trials and Reports Record Financial Results
Following the recent CE marking of its initial Immunohematology (IH) microarray, Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today provided an update on the status of its initial Serological Disease Screening (SDS)...
May 21, 2019 04:05 pm ET
Quotient Limited to Participate in the Jefferies 2019 Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop, will present at the Jefferies 2019 Healthcare Conference on Tuesday, June 4, 2019 at 8:30 a.m. ET in...
May 21, 2019 08:00 am ET
Quotient Ltd. Announces FDA Approval of Seven Additional Blood Bank Reagents
Quotient Limited (NASDAQ: QTNT), an established, commercial-stage diagnostics company (the Company), today announced the U.S. Food and Drug Administration (FDA) has approved the commercialization of seven additional blood bank reagents for extended...
May 14, 2019 04:05 pm ET
Quotient Limited to Report Fiscal Fourth Quarter and Full Year 2019 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal fourth quarter and full year ended March 31, 2019 will be released before market open on Tuesday, May 28, 2019. Quotient...
May 01, 2019 04:05 pm ET
Quotient Limited Receives European CE Mark for its Initial IH Microarray
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), headquartered in Eysins, Switzerland, today announced receipt of the CE Mark (Conformité Européenne) for its initial Immunohematology (IH) Microarray for use with...
Apr 24, 2019 04:05 pm ET
Quotient Limited Announces Initial SDS EU Field Trial Performance Data for MosaiQ™
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive EU field trial performance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS Microarray – Field...
Mar 07, 2019 08:30 am ET
Quotient Limited to Participate in the Cowen and Company 39th Annual Health Care Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chief Financial Officer, Chris Lindop, will present at the Cowen and Company 39th Annual Health Care Conference on Monday, March 11, 2019 at...
Feb 19, 2019 07:00 am ET
Quotient Limited to Host Investor Day and Ring Closing Bell at the NASDAQ on March 4, 2019
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company will host an Investor Day on Monday, March 4, 2019 from 1:00pm – 3:00pm ET, in New York, NY. Following the Investor Day, the Company’s Chief...
Feb 15, 2019 08:00 am ET
Quotient Limited to Participate in the 8th Annual SVB Leerink Global Healthcare Conference
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that today announced that the Company’s Chief Executive Officer, Franz Walt, will present at the 8th Annual SVB Leerink Global Healthcare Conference on Friday,...
Jan 31, 2019 06:00 am ET
Quotient Limited Provides an Update on Extended Immunohematology Microarray Performance and on the Commencement of the Initial Serological Disease Screening Field Trial together with Third Quarter Fis
Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today provided internal performance evaluation data for its extended immunohematology (IH) microarray, and announced the commencement of the...
Jan 17, 2019 08:00 am ET
Quotient Limited to Report Fiscal Third Quarter 2019 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2018, will be released before market open on Thursday, January 31, 2019. Quotient will...
Dec 11, 2018 04:30 pm ET
Quotient Limited Announces Receipt of the ISO 13485:2016 Certification of its State of the Art MosaiQ™ Microarray Manufacturing Facility
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported receipt of the formal ISO 13485:2016 certification for its state of the art MosaiQ™ multiplexing microarray manufacturing facility following the...
Dec 11, 2018 04:05 pm ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the closing of its previously announced underwritten public offering of 10,615,385 ordinary shares at a price to the public of $6.50 per share,...
Dec 06, 2018 09:05 pm ET
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the pricing of its previously announced underwritten public offering of 9,230,770 ordinary shares at a price to the public of $6.50 per share. The...
Dec 06, 2018 04:05 pm ET
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
Quotient Limited (NASDAQ:QTNT) (the Company), a commercial-stage diagnostics company, today announced the Company intends to commence an underwritten public offering of its ordinary shares. All of the ordinary shares to be sold in the offering will...
Dec 04, 2018 05:42 pm ET
Quotient Limited Announces Receipt of Consents to Modifications to the Company’s Senior Secured Notes
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today announced the receipt of consents from the holders of its Senior Secured Notes (the Notes) to certain amendments (the Proposed Amendments) to the indenture...
Dec 03, 2018 08:00 am ET
Quotient Limited Announces Initial MosaiQ™ SDS Verification and Validation Data
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), today reported positive Verification and Validation (V&V) concordance data for its initial MosaiQ™ Serological Disease Screening (SDS) Microarray. Initial SDS...
Nov 13, 2018 07:30 am ET
Report: Exploring Fundamental Drivers Behind Berry Petroleum, Quotient, Virco Manufacturing, Corvus Pharmaceuticals, Marine Products, and Hamilton Beach Brands Holding — New Horizons, Emerging Trends,
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Berry Petroleum Corporation (NASDAQ:BRY), Quotient Limited (NASDAQ:QTNT),...
Nov 05, 2018 06:00 am ET
Quotient Limited Reports Positive MosaiQ Audit Results and Instrument CE Mark with Second Quarter Fiscal 2019 Financial Results
Quotient Limited (NASDAQ: QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today reported the successful conclusion of the ISO 13485 : 2016 audit of its MosaiQ manufacturing facility and the CE marking of the MosaiQ...
Oct 31, 2018 08:00 am ET
Quotient Limited to Participate in the Jefferies 2018 London Healthcare Conference
Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chief Financial Officer, Chris Lindop, will present at the Jefferies 2018 London Healthcare Conference on Tuesday, November 14th, 2018 at 8:40 a.m....
Oct 22, 2018 08:00 am ET
Quotient Limited to Report Fiscal Second Quarter 2019 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ended September 30, 2018, will be released before market open on Monday, November 5, 2018. Quotient will...
Sep 26, 2018 08:00 am ET
Quotient Limited to Participate in the 2018 Cantor Fitzgerald Global Healthcare Conference
Quotient (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Franz Walt, will present at the 2018 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 3rd,...
Sep 25, 2018 08:00 am ET
Quotient Limited reports the submission of the initial IH CE mark filing and the successful completion of the key regulatory audits of its new BioCampus facility
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i) the submission of its completed dossier for the CE mark of its initial MosaiQ IH product as planned; and (ii) the successful completion of the key...
Aug 06, 2018 04:05 pm ET
Quotient Limited Reports Senior Note Issuance and Warrant Cash Inflows and updates on MosaiQ Development and First Quarter Fiscal 2019 Financial Results
Quotient Limited (NASDAQ:QTNT) (Quotient or the Company), a commercial-stage diagnostics company, today reported incremental cash inflows from the issuance of additional senior notes and the exercise of warrants sold in connection with its October...
Jul 24, 2018 04:05 pm ET
Quotient Limited to Report Fiscal First Quarter 2019 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ended June 30, 2018, will be released after market close on Monday, August 6, 2018. Quotient will host...
Jul 16, 2018 04:05 pm ET
Quotient Limited Announces Details of Investor Day
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced details of its investor day held at the NASDAQ headquarters in New York earlier today. Following the recent announcement of positive field trial data in a...
Jul 02, 2018 08:00 am ET
Quotient Limited Announces Completion of Senior Secured Notes Offering
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company (the Company), has completed the offering of up to $120.0 million aggregate principal amount of its 12% Senior Secured Notes due 2023 (the “Notes”). On June 29,...
Jun 18, 2018 04:05 pm ET
Quotient Limited to Host Investor Day on July 16, 2018
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it will host an Investor Day on Monday, July 16, 2018 from 9:00am – 1:00pm ET, in New York, NY. At the event, Franz Walt, Chief Executive Officer of...
Jun 18, 2018 06:30 am ET
Quotient Limited Reports Concordance Data from the MosaiQ European Field Trial
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported concordance data for the initial MosaiQ blood grouping microarray generated in its European field trial, which exceed the targeted criteria for submission for CE...
May 29, 2018 06:15 am ET
Quotient Limited Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Updates on CEO Appointment and MosaiQ™ European Field Trials
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercialization of MosaiQ and financial results for its fourth quarter and fiscal year ended March 31, 2018. The Company also...
May 29, 2018 06:00 am ET
Quotient Limited appoints Franz Walt as Chief Executive Officer
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt, as its Chief Executive Officer. Mr Walt who retired earlier this year as the President of Siemens Healthineers, Laboratory...
May 17, 2018 04:05 pm ET
Quotient Limited Reports Commencement of EU Blood Grouping Field Trial
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported that it has completed the verification and validation (V) phase for its initial blood grouping MosaiQ™ microarray (IH I) and has commenced its European field...
May 15, 2018 08:00 am ET
Quotient Limited to Report Fourth Quarter and Fiscal Full Year 2018 Financial Results and Host Conference Call
Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal full year ended March 31, 2018, will be released before market open on Tuesday, May 29, 2018. The...
Mar 26, 2018 04:15 pm ET
Quotient Limited Reports Blood Grouping Concordance Data From MosaiQ Verification and Validation Studies and Updates on the Completion of Its Sale Leaseback Transaction
JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported: (i) concordance data for the MosaiQ blood grouping microarray generated in recent V&V head-to-head studies; and (ii) completion of the...
Mar 26, 2018 04:05 pm ET
Quotient Limited Announces Retirement of Paul Cowan, Chairman and Chief Executive Officer; Franz Walt Named as Interim Chief Executive Officer
JERSEY, Channel Islands, March 26, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the retirement of Paul Cowan as its Chairman and Chief Executive Officer. Franz Walt, who recently retired as the President...
Mar 01, 2018 04:05 pm ET
Quotient Limited to Participate in the Cowen 38th Annual Global Health Care Conference
JERSEY, Channel Islands, March 01, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Cowen 38th Annual Global Health Care...
Feb 20, 2018 04:05 pm ET
Quotient Limited Announces the Sale and Leaseback of its Edinburgh, Scotland Manufacturing and R&D Facility
JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced it has entered into definitive agreements for the sale and leaseback of its recently completed Biocampus facility located near Edinburgh, Scotland.
Feb 20, 2018 08:00 am ET
Quotient Limited Announces Appointment of Franz Walt as Non-Executive Director
JERSEY, Channel Islands, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Franz Walt to its board of directors effective February 19, 2018
Feb 05, 2018 04:05 pm ET
Quotient Limited Updates on Status of MosaiQ Performance and Provides Third Quarter Fiscal 2018 Financial Results
JERSEY, Channel Islands, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued positive progress for the commercial scale-up of MosaiQ™ and its financial results for its fiscal third quarter and...
Jan 31, 2018 08:00 am ET
Quotient Limited to Participate in the LEERINK Partners 7th Annual Global Healthcare Conference
JERSEY, Channel Islands, Jan. 31, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the LEERINK Partners 7th Annual Global Healthcare...
Jan 23, 2018 08:00 am ET
Quotient Limited to Report Fiscal Third Quarter 2018 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2017, will be released after market close on Monday, February...
Jan 08, 2018 08:15 pm ET
Quotient Limited Reports Further Positive Data on its Initial Disease Screening Microarray and Provides Update on Blood Grouping
JERSEY, Channel Islands, Jan. 08, 2018 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported positive data for the initial MosaiQ disease screening microarray and provided an update on the ongoing internal verification and validation...
Dec 28, 2017 08:00 am ET
Quotient Limited to Participate in the 36th Annual J.P. Morgan Healthcare Conference
JERSEY, Channel Islands, Dec. 28, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the 36th Annual J.P. Morgan Healthcare Conference...
Nov 09, 2017 06:00 am ET
Quotient Limited to Participate in the Jefferies 2017 London Healthcare Conference
JERSEY, Channel Islands, Nov. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company's Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2017 London Healthcare Conference on...
Oct 30, 2017 04:05 pm ET
Quotient Limited Reports Second Quarter Fiscal 2018 Financial Results
MosaiQ project de-risked, Verification and Validation (“V&V”) “head-to-head” studies confirm targeted concordance levels for all blood grouping assaysEuropean field trials planned to commence prior to year endKey financing completed, raising up to $89 million – critical element of funding plan through commercialization22% Product revenue growth recorded during the quarter driven by the Reagent Business JERSEY, Channel Islands, Oct. 30, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported its financial results for the fiscal seco...
Aug 07, 2017 04:05 pm ET
Quotient Limited Reports Results From Ongoing MosaiQ Performance Evaluation Studies and First Quarter Fiscal 2018 Financial Results
Latest performance evaluation studies confirm substantial concordance with predicate technologies for blood grouping and initial disease screening applicationsEuropean field trials expected to be completed in CY17Record reagent revenues recorded during the quarter, exceeding guidanceSix new reagent products licensed by the FDA for sale in the U.S. JERSEY, Channel Islands, Aug. 07, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported progress on performance evaluation studies for MosaiQ™ and financial results for its fiscal first qua...
Jul 21, 2017 08:00 am ET
Quotient Limited to Report Continued Progress on the Commercial Scale-Up of MosaiQ™ and Fiscal First Quarter 2018 Financial Results and Host Conference Call
JERSEY, Channel Islands, July 21, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that an update on the results of internal verification and validation studies for the MosaiQ™ system, as well as financial results for its fiscal first quarter ended June 30, 2017, will be released after market close on Monday, August 7, 2017....
Jun 20, 2017 12:00 am ET
Quotient and Ortho Clinical Diagnostics to Present Symposium on Role of Extended Phenotyping in Blood Matching at ISBT
Quotient Limited (NASDAQ: QTNT), a commercial-stage diagnostics company, and Ortho Clinical Diagnostics ("Ortho"), a global leader of in vitro diagnostics, today announced they will jointly host a company-sponsored satellite symposium, "Improving Patient Care with Better-matched Blood," on Tuesday, June 20 from 12:00-1:30 p.m., during the 27th Regional Congress of the International Society of Blood Transfusion (ISBT). The ISBT Regional Congress takes place this week in Copenhagen, Denmark.
May 22, 2017 04:05 pm ET
Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ and Fourth Quarter and Fiscal Year 2017 Financial Results
Initial MosaiQ manufacturing system commissioned and validatedFirst “commercially ready” MosaiQ Instrument delivered to QuotientInternal validation of MosaiQ underway, with EU field trials expected in 3QCY17Fourth quarter revenues of $5.5 million and Product sales of $4.7 million, exceeding guidance$48 million equity raise successfully completed in April 2017 JERSEY, Channel Islands, May 22, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on the commercial scale-up of MosaiQ and financial results for its four...
May 09, 2017 08:00 am ET
Quotient Limited to Report Fourth Quarter and Fiscal Year 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, May 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ended March 31, 2017 will be released after market close on Monday, May 22, 2017....
Apr 10, 2017 04:05 pm ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 10, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 8,050,000 of its ordinary shares at a price to the public of $6.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional ordinary shares. The offering generated gross proceeds of approximately $48.3 million with Quotient receiving net proceeds of approximately $45.1 million after deducting underwriting discounts and commissions a...
Apr 04, 2017 04:01 pm ET
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, April 04, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares....
Mar 30, 2017 04:50 pm ET
Quotient Reports Continued Positive MosaiQ™ Performance Evaluation Results
Antibody Detection – enhanced detection versus predicate technologiesManufacturing of Microarrays for European field trials planned to commence in early AprilMosaiQ™ instrument development completed and formal validation has commencedCompletion of European field trials expected in mid 2017 JERSEY, Channel Islands, March 30, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced continued positive results from internal performance evaluation studies designed to evaluate the effectiveness of MosaiQ™ for blood grouping (both antigen typ...
Mar 23, 2017 04:05 pm ET
FDA Licenses Eight New Quotient Reagent Products for Sale in the U.S.
Products are rare antisera blood typing reagents developed and manufactured by QuotientU.S. commercialization of these products will extend the range and method of reagents available in the market for antigen phenotypingEquivalent products are already approved and commercialized outside of the U.S. Five additional rare antisera products are anticipated to be licensed for sale in the U.S. by the FDA later in 2017  JERSEY, Channel Islands, March 23, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that eight new rare antisera ...
Feb 09, 2017 04:05 pm ET
Quotient Limited Announces Appointment of Christopher Lindop as Chief Financial Officer
JERSEY, Channel Islands, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the appointment of Christopher Lindop as Chief Financial Officer.  Mr. Lindop will commence his new role on February 15, 2017....
Jan 24, 2017 08:00 am ET
Quotient Limited to Report Third Quarter Fiscal 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, Jan. 24, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2016 will be released after market close on Monday, February 6, 2017....
Jan 05, 2017 04:05 pm ET
Quotient Limited Reports Positive MosaiQ™ Results From Performance Evaluation Study for Blood Grouping
Root-cause investigation completed and corrective actions implementedPerformance evaluation study for antigen typing achieves targeted endpointsCompletion of European field trials expected in the first half of 2017 JERSEY, Channel Islands, Jan. 05, 2017 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported positive results from its MosaiQ™ performance evaluation study for antigen typing.  The Company continues to expect European field trials for MosaiQ™, for blood grouping and the initial disease screening panel, to be completed during ...
Nov 15, 2016 04:05 pm ET
Quotient Limited to Participate in the Jefferies 2016 London Healthcare Conference
JERSEY, Channel Islands, Nov. 15, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s Chairman and Chief Executive Officer, Paul Cowan, will present at the Jefferies 2016 London Healthcare Conference in London, UK on Thursday, November 17 at 4.00 p.m. GMT (11.00 a.m. Eastern Time)....
Nov 02, 2016 04:15 pm ET
Quotient Limited Announces CFO Transition
JERSEY, Channel Islands, Nov. 02, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, announced today that the company and Stephen Unger, Chief Financial Officer, have mutually agreed that he will leave Quotient to pursue other career opportunities. His last day will be November 2, 2016. The company intends to engage a leading executive recruiting firm to assist with its search for the next Chief Financial Officer....
Oct 31, 2016 04:15 pm ET
Quotient Limited Reports Continued Progress on the Commercial Scale-up of MosaiQ™ and Second Quarter Fiscal 2017 Financial Results
JERSEY, Channel Islands, Oct. 31, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported further progress on the commercial scale-up of MosaiQ™ and financial results for its fiscal second quarter and six months ended September 30, 2016....
Oct 21, 2016 08:30 am ET
Quotient Limited Announces Booth Tour at the 2016 AABB Annual Meeting and Provides Update of Expected Timing of Internal Evaluation Study Results
JERSEY, Channel Islands, Oct. 21, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the Company’s executive management team will host a booth tour on Monday, October 24th at 10:30 a.m. EDT at the 2016 AABB Annual Meeting being held October 22nd to 25th in Orlando, FL. The booth tour will include an overview of Quotient’s MosaiQ™ next-generation automation platform for blood grouping and disease screening....
Oct 17, 2016 08:30 am ET
Quotient Limited to Report Second Quarter Fiscal 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, Oct. 17, 2016 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal second quarter ending September 30, 2016 will be released after market close on Monday, October 31, 2016....
Oct 14, 2016 04:01 pm ET
Quotient Limited Announces $120 Million Secured Debt Financing
JERSEY, Channel Islands, Oct. 14, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (“Quotient”) (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the completion of a private placement of up to $120 million of 12% Senior Secured Notes due 2023. At the initial closing of the transaction, Quotient issued $84 million of notes and received net proceeds of approximately $79 million after expenses. Quotient will issue an additional $36 million of notes to note purchasers upon public announcement of field trial results for the MosaiQ™ IH Microarray that demonstrates greater than 99% ...
Sep 08, 2016 04:05 pm ET
Quotient Limited Announces Successful Validation of the Initial Manufacturing System for MosaiQ™ Microarrays
MosaiQTM manufacturing system operating in accordance with design requirements Ongoing evaluation of MosaiQTM methodology continues to demonstrate concordance levels in excess of 99.0% for key blood group antigen specificities JERSEY, Channel Islands, Sept. 08, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the successful completion of equipment validation of the initial manufacturing system for MosaiQ™ Microarrays. The manufacturing system consists of three key elements: i) the print system; ii) the wet process; and iii) t...
Aug 08, 2016 04:15 pm ET
Quotient Limited Reports Further Progress on the Commercial Scale-up of MosaiQ™ and First Quarter Fiscal 2017 Financial Results
Facility modification completed – humidity control successfully resolved issue previously impacting final assembly of MosaiQ™ consumablesValidation of the initial manufacturing system for MosaiQ™ consumables planned for completion by the end of August 2016Instruments incorporating “field trial ready” software delivered to Quotient for evaluation (European field trials scheduled for 4QCY16)Fiscal first quarter product sales of $5.7M, representing growth of 18% year-over-yearFiscal year 2017 total revenue guidance increased to $21.7M to $22.7M, representing growth of 17% to 23% year-over-year ...
Aug 03, 2016 04:05 pm ET
Quotient Limited Announces Closing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, Aug. 03, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the closing of its underwritten public offering of 3,220,000 of its ordinary shares at a price to the public of $5.50 per share, which includes the exercise in full by the underwriter of its option to purchase up to 420,000 additional ordinary shares. The offering generated gross proceeds of approximately $17.7 with Quotient receiving net proceeds of approximately $16.3 million after deducting underwriting discounts and estimated offering expens...
Aug 01, 2016 08:30 am ET
Quotient Limited to Report First Quarter Fiscal 2017 Financial Results and Host Conference Call
JERSEY, Channel Islands, Aug. 01, 2016 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal first quarter ending June 30, 2016 will be released after market close on Monday, August 8th, 2016....
Jul 29, 2016 09:15 am ET
Quotient Limited Announces Pricing of Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, July 29, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced the pricing of an underwritten public offering of 2,800,000 of its ordinary shares at a price to the public of $5.50 per share. The net proceeds to Quotient from this offering are expected to be $14.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by Quotient. Quotient has also granted the underwriter a 30-day option to purchase up to an additional 420,000 of its ordinary shares. T...
Jul 28, 2016 04:10 pm ET
Quotient Limited Announces Proposed Underwritten Offering of Ordinary Shares
JERSEY, Channel Islands, July 28, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that it intends to commence an underwritten public offering of its ordinary shares....
Jul 11, 2016 04:15 pm ET
Quotient Limited Provides Update on the MosaiQ™ Development Plan and Reports Preliminary Fiscal First Quarter 2017 Revenues
Manufacturing system for MosaiQ™ consumables meeting design expectationsField trial instruments successfully pass rigorous internal evaluationMinor manufacturing facility modification recently identified and underway; expected commencement of European field trials to be delayed by six to eight weeks JERSEY, Channel Islands, July 11, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today provided an update of the plan for commercial scale up of MosaiQ™, including the status of validation activities associated with the initial manufacturing sy...
May 31, 2016 08:30 am ET
Quotient Limited to Participate in Jefferies 2016 Global Healthcare Conference
JERSEY, Channel Islands, May 31, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company’s Chairman & CEO, Paul Cowan, will present at the Jefferies 2016 Global Healthcare Conference in New York City at 2:00 p.m. Eastern Time on Wednesday, June 8. The presentation will be webcast live on the company’s website at www.quotientbd.com....
May 23, 2016 04:17 pm ET
Quotient Limited Reports Continued Progress on the Development of MosaiQ™ and Fourth Quarter and Fiscal Year 2016 Financial Results
Completed commissioning of initial manufacturing system for MosaiQTM consumablesFirst field trial instruments received for internal evaluation and validationGenerated positive study results for remaining four serological disease screening assaysHIV, HBV, HCV and West Nile virus successfully detected using the MosaiQ™ methodology for molecular disease screeningFiscal fourth quarter product sales of $4.5M, exceeding guidance JERSEY, Channel Islands, May 23, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today reported continued progress on ...
May 11, 2016 08:02 am ET
Quotient Limited to Report Fourth Quarter Fiscal 2016 Financial Results and Host Conference Call
JERSEY, Channel Islands, May 11, 2016 (GLOBE NEWSWIRE) -- Quotient Limited  (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fourth quarter and fiscal year ending March 31, 2016 will be released after market close on Monday, May 23rd, 2016....
May 11, 2016 08:00 am ET
Quotient Limited to Participate in UBS Global Healthcare Conference
JERSEY, Channel Islands, May 11, 2016 (GLOBE NEWSWIRE) -- Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that the company’s Chairman & CEO, Paul Cowan, will present at the UBS Global Healthcare Conference in New York City at 4:00 p.m. Eastern Time on Tuesday, May 24, 2016....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.